197 related articles for article (PubMed ID: 31048326)
21. Acute kidney injury from immune checkpoint inhibitor use.
Gordon L; Dokouhaki P; Hagel K; Prasad B
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31653633
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
23. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
24. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
26. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab-induced renal granulomatous arteritis: a case report.
Lemoine M; Dilly B; Curie A; Hébert V; Laurent C; Hanoy M; Grangé S; Guerrot D; François A; Bertrand D
BMC Nephrol; 2019 Oct; 20(1):366. PubMed ID: 31604452
[TBL] [Abstract][Full Text] [Related]
28. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
Nakatani Y; Kawakami H; Ichikawa M; Yamamoto S; Otsuka Y; Mashiko A; Takashima Y; Ito A; Nakagawa K; Arima S
Invest New Drugs; 2018 Aug; 36(4):726-731. PubMed ID: 29623482
[TBL] [Abstract][Full Text] [Related]
30. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
[TBL] [Abstract][Full Text] [Related]
31. Renal effects of immune checkpoint inhibitors.
Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
[TBL] [Abstract][Full Text] [Related]
32. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
Azari AE; Stratton R; Singh A
Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
[No Abstract] [Full Text] [Related]
33. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
34. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
35. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
36. Enteritis with immune checkpoint inhibitor use.
Sanders D; Webber D; Chatur N
CMAJ; 2019 Oct; 191(40):E1106. PubMed ID: 31591098
[No Abstract] [Full Text] [Related]
37. Immunotherapy in colorectal cancer with mismatch repair deficiency.
Overman MJ
Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
[No Abstract] [Full Text] [Related]
38. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
39. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
[TBL] [Abstract][Full Text] [Related]
40. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]